Market revenue in 2023 | USD 33.5 million |
Market revenue in 2030 | USD 79.7 million |
Growth rate | 13.2% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 55.82% in 2023. Horizon Databook has segmented the Norway structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
Norway's structural heart devices market is witnessing notable growth driven by various factors, including the aging population, increasing prevalence of CVDs, and advancements in medical technology. The Norwegian healthcare system's emphasis on innovation and patient-centric care further propels this market forward.
TAVI plays a pivotal role in structural heart devices by offering less invasive treatment options for conditions like aortic stenosis. TAVI procedures involve implanting a collapsible valve through a catheter, thereby reducing recovery time, hospital stays, and overall procedural risks compared to traditional open-heart surgery.
Norway's progressive healthcare policies, coupled with a growing demand for minimally invasive interventions, position it as a key market for structural heart devices like TAVI, meeting the evolving needs of patients and healthcare providers alike.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway structural heart devices market , including forecasts for subscribers. This country databook contains high-level insights into Norway structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account